Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center

In conclusion, high-risk CBF-AML patients must be identified before treatment. D816/D820 mutation, MRD> 0.1% at the end of two cycles of consolidation chemotherapy predicted poor survivals, and allo-HSCT can improve the survival of properly identified patients.
Source: Annals of Hematology - Category: Hematology Source Type: research